Altimmune Inc. (ALT) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Altimmune Inc. (NASDAQ: ALT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $2.02 (-0.98% 1D, market cap $396.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ALT ranks #970 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALT carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.7%. By comparison, AVTX (Avalo Therapeutics Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $384.5M) and ASMB (Assembly Biosciences Inc.) posts a E grade (16/100 RQD, P/E N/A, ROIC -6.5%, cap $409.9M). Among the 5-stock peer group, ALT leads on earnings multiple (N/A) while ASMB leads on capital efficiency (-6.5% ROIC).
Per ALT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326190), Altimmune Inc. generated $41.0K in revenue (+105.0% YoY), -$88.1M in net income, and -$67.5M in free cash flow against $279.9M in total assets and $34.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Altman Z-Score 1.30 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ALT currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.79) and Max Pain ($2.12) forces dealer call-delta covering toward $6.76.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Altimmune Inc. (ALT) slipped -0.98% to $2.02, trading at 2% of its 52-week range ($1.99 – $6.44). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill,
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +105.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ALT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ALT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Altimmune Inc. (ALT) ranks #970 by composite RQD confidence (21/100, grade E) and #475 by equity capitalization ($396.8M). Within this direct 5-issuer industry benchmark cohort, ALT leads on earnings valuation at N/A trailing P/E, while ASMB leads on capital efficiency and profitability with -6.5% ROIC and — gross margin. RZLT currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with ALT at 21/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALT
ACTIVE
Altimmune Inc. | E | 21/100 | — | — | -34.7% | -0.98% | $396.8M | Benchmark Subject |
| AVTX Avalo Therapeutics Inc. | E | 17/100 | — | — | -35.0% | +2.09% | $384.5M | /avtx-vs-alt → |
| ASMB Assembly Biosciences Inc. | E | 16/100 | — | — | -6.5% | -3.08% | $409.9M | /asmb-vs-alt → |
| RZLT Rezolute Inc. (NV) | D- | 37/100 | — | — | -35.0% | -1.77% | $382.1M | /rzlt-vs-alt → |
| RLMD Relmada Therapeutics Inc. | E | 30/100 | — | — | -35.0% | +7.26% | $381.9M | /rlmd-vs-alt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Altimmune Inc. (ALT) reported GAAP revenue of $41.0K (+105.0% vs. FY2024 revenue of $20.0K , and -90.4% cumulative change since FY2023) , GAAP net income of -$88.1M, operating cash flow of -$67.5M, and free cash flow of -$67.5M (+15.4% YoY). On the balance sheet, ALT closed FY2025 with $279.9M in total assets against $34.3M in total debt (Altman Z-Score: 1.30, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $41.0K | -$88.1M | -$67.5M | -$67.5M | $279.9M | $34.3M |
| FY2024 (FY) | 2024-12-31 | $20.0K | -$95.1M | -$79.8M | -$79.8M | $139.3M | — |
| FY2023 (FY) | 2023-12-31 | $426.0K | -$88.4M | -$75.8M | -$75.8M | — | — |
As of 2026-11-03, Altimmune Inc. (NASDAQ: ALT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $2.02 (-0.98% 1D, market cap $396.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ALT ranks #970 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALT carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -34.7%. By comparison, AVTX (Avalo Therapeutics Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $384.5M) and ASMB (Assembly Biosciences Inc.) posts a E grade (16/100 RQD, P/E N/A, ROIC -6.5%, cap $409.9M). Among the 5-stock peer group, ALT leads on earnings multiple (N/A) while ASMB leads on capital efficiency (-6.5% ROIC).
Per ALT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001326190), Altimmune Inc. generated $41.0K in revenue (+105.0% YoY), -$88.1M in net income, and -$67.5M in free cash flow against $279.9M in total assets and $34.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ALT last traded at $2.02 (-0.98% on volume of 2,740,663 shares), positioning the stock -27.60% below its 50-day simple moving average ($2.79) and -38.04% below its 200-day simple moving average ($3.26). Across its 52-week range of $1.99 to $6.44, ALT sits at the 0.7% percentile with a 14-day RSI of 30.9 (OVERSOLD (<32)) and an implied next-earnings move of ±10.7% ($1.80 to $2.24).
ALT carries an RQD Score of 22 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
Taken together, the pillars point to a high-risk profile: weak cash generation, limited institutional and insider support, and a distressed-leaning Altman score. Upside drivers would need to come from a shift in cash-flow trajectory or external catalysts, neither of which is established in the source data. Valuation tradeoffs are unresolved because P/E and EV/EBITDA are unavailable.
Altimmune Inc. (ALT) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations,..4B. Reported revenue was — in FY 2025 and FY 2024 and $0.4M in FY 2023. —: product lines, customer base, and revenue model detail.
Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%. Per the RQD rating, ROIC is -34.7%. Per the RQD rating, the Altman Z-Score is 1.3 and the Piotroski F-Score is 5/9, with Debt/Equity at 0.15. The reported losses and negative free cash flow across all three periods indicate sustained cash consumption.
Upstream and downstream dependencies: — Sector correlations beyond the stated beta of 1.0: — 2nd-order bottlenecks: — Investors should monitor pemvidutide trial and data readouts as the primary pipeline-linked ripple, since that is the only referenced development that could affect cash-burn trajectory.
Real-time company headlines, analyst actions, and sector developments for Altimmune Inc. (ALT) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Altimmune Inc. (ALT) market action, institutional positioning, and fundamental catalysts.
Pemvidutide is slated for new data presentation at AASLD The Liver Meeting 2026, a potential pipeline catalyst.. When you look under the hood at ALT, Fundamental Cash Engine is 5/20 with 0.0% gross margins and -34.7% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $6.44. My 12M target is $2.59.
Both sides have a point here — ALT's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Careful chasing ALT at $2.04. Negative ROIC of -34.7% and FCF yield of -16.23% with an Altman Z-Score of 1.3 signal sustained cash burn and distress-range balance sheet risk.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.75 on multiple compression.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).